The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Deregulation of Hippo kinase signalling in Human hepatic malignancies
Open accessAbstract
Background/Aims: Hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and hepatoblastoma (HB) are the main hepatic malignancies with limited treatment options and high mortality. Recent studies have implicated H ippo kinase pathway in cancer development, but detailed analysis of H ippo kinase signalling in human hepatic malignancies, especially CC and HB, is lacking. Methods: We investigated H ippo kinase signalling in HCC, CC and HB using cells and patient samples. Results: Increased expression of yes‐associated protein (Y ap), the downstream effector of the H ippo kinase pathway, was observed in HCC cells, and si RNA‐mediated knockdown of Y ap resulted in decreased survival of HCC cells. The density‐dependent activation of Hippo kinase pathway characteristic of normal cells was not observed in HCC cells and CCLP cells, a cholangiocarcinoma cell line. Immunohistochemistry of Y ap in HCC, CC and HB tissues indicated extensive nuclear localization of Y ap in majority of tissues. Western blot analysis performed using total cell extracts from patient samples and normal livers showed extensive activation of Y ap. Marked induction of G lypican‐3, CTGF and S urvivin, the three Y ap target genes was observed in the tumour samples. Further analysis revealed significant decrease in expression and activity of Lats kinase, the main upstream regulator of Y ap. However, no change in activation of Mst‐2 kinase, the upstream regulator of Lats kinase was observed. Conclusions: These data show that Y ap induction mediated by inactivation of L ats is observed in hepatic malignancies. These studies highlight H ippo kinase pathway as a novel therapeutic target for hepatic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Zhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R. A., & Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.06.015 · Cited by 804
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
Hippo Pathway Activity Influences Liver Cell Fate
Yimlamai, D., Christodoulou, C., Galli, G. G., Yanger, K., Pepe-Mooney, B., Gurung, B., Shrestha, K., Cahan, P., Stanger, B. Z., & Camargo, F. D. (2014) · Cell · doi:10.1016/j.cell.2014.03.060 · Cited by 857
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Zhou, F., Shang, W., Yu, X., & Tian, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21455 · Cited by 397
Metadata
- Authors
- Li, H., Wolfe, A., Septer, S., Edwards, G., Zhong, X., Bashar Abdulkarim, A., Ranganathan, S., & Apte, U.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2011-10-20
- Volume
- 32
- Issue
- 1
- Pages
- 38-47
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2170664715
- Cited by
- 168
- References
- 2
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deregulation of Hippo kinase signalling in Human hepatic malignancies. https://app.cochat.ai/papers/10.1111/j.1478-3231.2011.02646.x
- The paper
- Li, H., Wolfe, A., Septer, S., Edwards, G., Zhong, X., Bashar Abdulkarim, A., Ranganathan, S., & Apte, U. (2012). Deregulation of Hippo kinase signalling in Human hepatic malignancies. Liver International. https://doi.org/10.1111/j.1478-3231.2011.02646.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.